Botulinum toxin A and chronic low back pain

Objectives: To investigate the efficacy of botulinum toxin A in chronic low back pain and associated disabilities. Methods: Thirty-one consecutive patients with chronic low back pain who met the inclusion criteria were studied: 15 received 200 units of botulinum toxin type A, 40 units/site at five lumbar paravertebral levels on the side of maximum discomfort, and 16 received normal saline. Each patient’s baseline level of pain and degree of disability was documented using the visual analogue scale (VAS) and the Oswestry Low Back Pain Questionnaire (OLBPQ). The authors reevaluated the patients at 3 and 8 weeks (visual analogue scale) and at 8 weeks (OLBPQ). Results: At 3 weeks, 11 of 15 patients who received botulinum toxin (73.3%) had >50% pain relief vs four of 16 (25%) in the saline group (p = 0.012). At 8 weeks, nine of 15 (60%) in the botulinum toxin group and two of 16 (12.5%) in the saline group had relief (p = 0.009). Repeat OLBPQ at 8 weeks showed improvement in 10 of 15 (66.7%) in the botulinum toxin group vs three of 16 (18.8%) in the saline group (p = 0.011). No patient experienced side effects. Conclusion: Paravertebral administration of botulinum toxin A in patients with chronic low back pain relieved pain and improved function at 3 and 8 weeks after treatment.

[1]  M. Hallett.  How does botulinum toxin work? , 2000, Annals of neurology.

[2]  B. Guyer.  Mechanism of botulinum toxin in the relief of chronic pain , 1999, Current review of pain.

[3]  M. Schwartz,et al.  Treatment of whiplash associated neck pain with botulinum toxin-A: report of 8 cases. , 1999, The Journal of rheumatology.

[4]  J. Eisenberg.  Agency for Health Care Policy and Research. , 1999, Medical care.

[5]  P. Goolkasian,et al.  A Randomized, Double‐Blind, Prospective Pilot Study of Botulinum Toxin Injection for Refractory, Unilateral, Cervicothoracic, Paraspinal, Myofascial Pain Syndrome , 1998, Spine.

[6]  C. Comella,et al.  Extensor truncal dystonia: Successful treatment with botulinum toxin injections , 1998, Movement disorders : official journal of the Movement Disorder Society.

[7]  J. Dutton,et al.  Botulinum-A toxin in the treatment of craniocervical muscle spasms: short- and long-term, local and systemic effects. , 1996, Survey of ophthalmology.

[8]  S Gates,et al.  Development of the Practice Guidelines for Acute Low Back Problems in Adults , 1995, Orthopedic nursing.

[9]  B. Jabbari,et al.  Botulinum toxin A for spasticity, muscle spasms, and rigidity , 1995, Neurology.

[10]  J. Fairbank,et al.  Randomised controlled trial for evaluation of fitness programme for patients with chronic low back pain , 1995, BMJ.

[11]  R. Deyo,et al.  Low pack pain , 1995 .

[12]  W. P. Cheshire,et al.  Botulinum toxin in the treatment of myofascial pain syndrome , 1994, Pain.

[13]  Donald D. Price,et al.  A comparison of pain measurement characteristics of mechanical visual analogue and simple numerical rating scales , 1994, Pain.

[14]  M. Hallett,et al.  Long‐term botulinum toxin treatment of focal hand dystonia , 1994, Neurology.

[15]  W. Roberts,et al.  Sympathetic activation of cat spinal neurons responsive to noxious stimulation of deep tissues in the low back , 1994, Pain.

[16]  P. Errico,et al.  Botulinum A toxin effects on rat jaw muscle spindles. , 1993, Acta oto-laryngologica.

[17]  B. Jabbari,et al.  Significant improvement of stiff‐person syndrome after paraspinal injection of botulinum toxin A , 1993, Movement disorders : official journal of the Movement Disorder Society.

[18]  J W Frymoyer,et al.  Predicting disability from low back pain. , 1992, Clinical orthopaedics and related research.

[19]  Newest knowledge of low back pain--solutions in sight. , 1992, Clinical orthopaedics and related research.

[20]  Kuslich Sd,et al.  The tissue origin of low back pain and sciatica: a report of pain response to tissue stimulation during operations on the lumbar spine using local anesthesia. , 1991 .

[21]  S D Kuslich,et al.  The tissue origin of low back pain and sciatica: a report of pain response to tissue stimulation during operations on the lumbar spine using local anesthesia. , 1991, The Orthopedic clinics of North America.

[22]  M. Brin,et al.  Double‐blind, placebo‐controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis , 1990, Neurology.

[23]  D. Borenstein,et al.  Cyclobenzaprine and naproxen versus naproxen alone in the treatment of acute low back pain and muscle spasm. , 1990, Clinical therapeutics.

[24]  W. Roberts.  A hypothesis on the physiological basis for causalgia and related pains , 1986, Pain.

[25]  R. Sherman.  RELATIONSHIPS BETWEEN STRENGTH OF LOW BACK MUSCLE CONTRACTION AND REPORTED INTENSITY OF CHRONIC LOW BACK PAIN , 1985 .

[26]  Arie Nouwen,et al.  The relationship between paraspinal EMG and chronic low back pain , 1984, Pain.

[27]  A. Glaros,et al.  Paralumbar muscle activity in chronic low back pain. , 1981, Archives of physical medicine and rehabilitation.

[28]  J C Fairbank,et al.  The Oswestry low back pain disability questionnaire. , 1980, Physiotherapy.

[29]  D. Ha.  EMG fatigue curves in postural muscles. A possible etiology for idiopathic low back pain. , 1968 .

[30]  H. Devries.  EMG fatigue curves in postural muscles. A possible etiology for idiopathic low back pain. , 1968, American journal of physical medicine.

[31]  K. Hingorani.  Diazepam in backache. A double-blind controlled trial. , 1966, Annals of physical medicine.

[32]  M. Rand,et al.  Impairment of Sympathetic Transmission by Botulinum Toxin , 1965, Nature.